File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: JTV-519 Japan tobacco

TitleJTV-519 Japan tobacco
Authors
Issue Date2001
PublisherCurrent Drugs Ltd. The Journal's web site is located at http://www.biomedcentral.com/1472-4472
Citation
Current Opinion In Investigational Drugs, 2001, v. 2 n. 7, p. 936-939 How to Cite?
AbstractJapan Tobacco is developing the mixed action ion channel blocker, JTV-519, which has potential use as an antiarrhythmic. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998; phase II trials started in the fourth quarter of 1998 for the potential treatment of myocardial infarction. Studies have shown that JTV-519 has a strong cardioprotective effect against catecholamine-induced myocardial injury and against ischemia/reperfusion injury. In experimental myofibrillar overcontraction models, it demonstrated greater cardioprotectant effects than propranolol, verapamil and diltiazem.
Persistent Identifierhttp://hdl.handle.net/10722/78393
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorTse, HFen_HK
dc.contributor.authorLam, WFen_HK
dc.date.accessioned2010-09-06T07:42:23Z-
dc.date.available2010-09-06T07:42:23Z-
dc.date.issued2001en_HK
dc.identifier.citationCurrent Opinion In Investigational Drugs, 2001, v. 2 n. 7, p. 936-939en_HK
dc.identifier.issn0967-8298en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78393-
dc.description.abstractJapan Tobacco is developing the mixed action ion channel blocker, JTV-519, which has potential use as an antiarrhythmic. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998; phase II trials started in the fourth quarter of 1998 for the potential treatment of myocardial infarction. Studies have shown that JTV-519 has a strong cardioprotective effect against catecholamine-induced myocardial injury and against ischemia/reperfusion injury. In experimental myofibrillar overcontraction models, it demonstrated greater cardioprotectant effects than propranolol, verapamil and diltiazem.en_HK
dc.languageengen_HK
dc.publisherCurrent Drugs Ltd. The Journal's web site is located at http://www.biomedcentral.com/1472-4472en_HK
dc.relation.ispartofCurrent Opinion in Investigational Drugsen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAnnexin A5 - metabolism - physiologyen_HK
dc.subject.meshAnti-Arrhythmia Agents - metabolism - pharmacologyen_HK
dc.subject.meshCalcium - metabolismen_HK
dc.subject.meshCardiotonic Agents - metabolism - pharmacologyen_HK
dc.subject.meshCell Death - drug effectsen_HK
dc.subject.meshIon Channels - antagonists & inhibitorsen_HK
dc.subject.meshMembrane Potentials - drug effectsen_HK
dc.subject.meshMyocardial Reperfusion Injury - drug therapyen_HK
dc.subject.meshMyocardial Stunning - drug therapyen_HK
dc.subject.meshMyocardium - pathologyen_HK
dc.subject.meshProtein Kinase C - metabolism - physiologyen_HK
dc.subject.meshThiazepines - metabolism - pharmacologyen_HK
dc.titleJTV-519 Japan tobaccoen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1472-4472&volume=2&spage=936&epage=9&date=2001&atitle=JTV-519+Japan+Tobaccoen_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid11757794-
dc.identifier.scopuseid_2-s2.0-0034926648en_HK
dc.identifier.hkuros65490en_HK
dc.identifier.hkuros115094-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034926648&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue7en_HK
dc.identifier.spage936en_HK
dc.identifier.epage939en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridLam, WF=7203021850en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats